Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra, Inc. is proposing to be acquired by Boston Scientific Corporation pursuant to an Agreement and Plan of Merger dated January 14, 2026, under which Penumbra will become a wholly owned subsidiary of Boston Scientific. Each issued and outstanding Penumbra share (other than excluded or dissenting shares) will convert into the right to receive either $374.00 in cash or 3.8721 Boston Scientific Shares, subject to a proration mechanism that allocates 73.26% of shares to cash consideration and 26.74% to stock consideration.
The parties valued the consideration at $374.00 per Penumbra share at announcement. Based on shares outstanding as of March 27, 2026, Boston Scientific expects to issue approximately 43,866,267 Boston Scientific Shares and former Penumbra holders would own ~2.87% of Boston Scientific post-close. The special meeting of Penumbra stockholders is scheduled for May 6, 2026, and the proxy/prospectus contains detailed election procedures, regulatory conditions, termination fees and risk factors.
Penumbra Inc Schedule 13G/A: The Vanguard Group files an amendment reporting 0 shares beneficially owned—0% of Common Stock following an internal realignment.
The amendment explains that, effective January 12, 2026, certain Vanguard subsidiaries and business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim on 03/27/2026.
Penumbra Inc President Shruthi Narayan reported a routine tax-withholding share disposition. On the vesting of restricted stock units, 117 shares of common stock were withheld by the company to satisfy tax obligations at an indicated value of $336.18 per share. After this non-market event, Narayan directly holds 30,755 shares of Penumbra common stock, and a portion of these shares remains subject to vesting.
Penumbra Inc executive Johanna Roberts had 186 shares of Common Stock withheld by the company to cover taxes on vesting restricted stock units. The shares were valued at $336.18 per share for this tax-withholding transaction. After this non-market disposition, she directly holds 67,298 shares of Penumbra Common Stock.
This event reflects routine tax withholding related to equity compensation rather than an open-market sale or discretionary trading decision.
Penumbra Inc Chief Financial Officer Maggie Yuen reported a routine tax-related share disposition. The company withheld 186 shares of common stock at $336.18 per share to satisfy tax obligations tied to vesting restricted stock units. After this withholding, she directly holds 18,167 common shares.
Penumbra Inc’s Chief Accounting Officer Lambert Shiu reported a routine tax-related share disposition. On March 15, 2026, 150 shares of common stock were withheld by the company at $336.18 per share to satisfy tax obligations from vesting restricted stock units. After this tax-withholding transaction, Shiu directly owns 39,323 shares of Penumbra common stock and indirectly holds 300 shares through a spouse’s IRA.
Penumbra Inc’s chief financial officer, Maggie Yuen, sold 2,432 shares of common stock in an open-market transaction at $342.30 per share. The sale was carried out under her Rule 10b5-1 trading plan, which pre-arranges trades. After this transaction, she directly owns 18,353 shares, and a portion of these shares is subject to vesting.
Boston Scientific discussed the strategic rationale and integration approach for its proposed acquisition of Penumbra during a TD Cowen conference Q&A on March 3, 2026. Executives said Penumbra would operate as a stand-alone global business unit within Boston Scientific’s cardiovascular/ICTx portfolio, retaining its commercial team and leadership. Management highlighted opportunities to scale Penumbra outside the U.S., leverage Boston Scientific’s supply chain (including Costa Rica manufacturing), and cross-sell complementary products across neurovascular, thrombectomy, vascular and interventional cardiology accounts. The transaction remains subject to regulatory review and customary closing conditions; Boston Scientific referenced a Form S-4/proxy filing in connection with the proposed transaction.
PEN: Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sales of Common stock. The filing lists 900 shares sold as Exercised Shares on 03/05/2025, 1,112 Restricted Stock dated 12/16/2020, and 420 shares from an Employee Stock Purchase Plan dated 11/19/2021.
Penumbra, Inc. reports strong 2025 growth and outlines a planned sale to Boston Scientific. Revenue reached $1,403.7 million, up 17.5% from 2024, driven by thrombectomy products at $947.9 million and embolization/access at $455.7 million. Income from operations rose to $189.2 million, rebounding from 2024 when a $115.3 million impairment tied to exiting the immersive healthcare business depressed results. The company has agreed to a merger valuing it at about $14.5 billion, with shareholders able to elect $374 in cash or 3.8721 Boston Scientific shares per Penumbra share, subject to an overall mix of roughly 73% cash and 27% stock. As of February 4, 2026, Penumbra had 39,243,053 common shares outstanding. The filing also details large addressable markets in thrombectomy and embolization, an expanding global manufacturing and sales footprint, and extensive regulatory and intellectual property protections, while highlighting risks around competition, reimbursement, regulation and execution of the proposed merger.